Compare Toro Company (The) Common Stock (TTC) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Toro Company (The) Common Stock vs Twist Bioscience Corp — how do they compare? Toro Company (The) Common Stock trades at $98.27 (market cap $9.27B), while Twist Bioscience Corp trades at $146 (market cap $10.03B). The key difference: Toro Company (The) Common Stock and Twist Bioscience Corp are close in size by market cap, and Toro Company (The) Common Stock pays a 1.59% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Toro Company (The) Common Stock for 0 Days and Twist Bioscience Corp for 27 Days on average.
| TTC | TWST | |
|---|---|---|
Market Cap | $9.27B | $10.03B |
Volume | 688,325 | 1,528,940 |
Sector | Industrials | Health |
52-Week High | $101.76 | $205.00 |
52-Week Low | $67.99 | $25.45 |
Typical Hold Time | 0 Days | 27 Days |
Enterprise Value | $10.17B | $9.96B |
Dividend Yield | 1.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Toro Company (TTC) trades at $97.88, up 1.27% with strong technical momentum above its 50-day moving average. The company demonstrates solid fundamentals with consistent earnings beats, including Q2 2026 EPS of $1.33 beating expectations of $1.31, and raised full-year guidance. Revenue growth of 8.4% in Q3 2026 to $1.23 billion reflects robust demand across professional and residential segments, supported by infrastructure and automation initiatives under new CEO leadership.
Toro presents a balanced investment case with 36% analyst buy ratings and $117.50 price target suggesting 20% upside. However, execution risks from inflation, tariffs, and competitive pressures warrant caution. The stock's premium valuation (P/E 26.17) requires sustained earnings growth, making Q3 2026 results critical for validating current momentum.
TWST trades at $148.16, down 2.44% today, with a bullish technical signal but negative earnings trends. Recent news highlights its role in Eli Lilly's AI drug discovery platform, driving investor optimism. Revenue growth is strong, reaching $376.57M in 2025, but net losses persist, with a margin of -20.63%. The stock faces resistance near $154, with support at $146.
Outlook is mixed: analyst consensus is bullish with a $153.70 price target, but profitability challenges and cash flow deficits pose risks. The AI collaboration offers growth potential, yet execution and margin improvement are critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Toro Company (The) Common Stock
The Toro Company designs, manufactures, and markets equipment for turf maintenance, snow and ice management, landscaping, construction, and irrigation. Its products serve golf courses, sports fields, and residential and commercial properties in more than 125 countries.
Read more on TTC →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
